Establishing a Standardized Dataset for Psychedelic Medicine

A Delphi Expert-Consensus study The Psychedelic Mental Health Access Alliance (PMHA), UC Berkeley’s Collaborative on the Economics of Psychedelics (CEP), and McGill University are launching a Delphi Expert-Consensus Study to develop a standardized set of measures and variables for psychedelic-assisted therapy across diverse clinical and research settings.This initiative responds to a critical need: current approaches to data collection vary widely between research studies and are inconsistently applied in clinical settings. By creating a set of standardized measures and variables, this project aims to:Improve the comparability of scientific studiesEnable “real-world” effectiveness researchGuide best practices in clinical and community-based settingsSupport policy and insurance decision-makingWhy this matters:Supports effectiveness research necessary for public and private insurance coverageImproves data comparability across clinics, studies, and patient populationsGuides evidence-informed practice in a rapidly evolving therapeutic fieldLays the groundwork for safety monitoring, reimbursement models, and scalable care systemsA Delphi survey is a structured, multi-round research process that uses anonymous feedback to build expert consensus. This process will:Involve at least three iterative rounds of structured input and feedbackEngage diverse stakeholders, including:CliniciansResearchersHealth economistsMedicaid and health policy expertsProduce a consensus-based framework to guide effective and practical implementation of psychedelic-assisted therapy data collection tailored to specific contextsWe are recruiting a multidisciplinary panel of experts to ensure balanced representation, including:Clinicians – frontline experience with psychedelic therapy deliveryResearchers – expertise in mental health, public health, and health economicsPolicy/Health Systems Experts – focus on safety, regulation, and cost-effectivenessMedicaid Experts – specialization in coverage and integration into public insurance programsGet involved:
If you’re a clinician, researcher, policymaker, or Medicaid expert with relevant experience, we invite you to complete the form linked here to express your interest in this groundbreaking project to shape the future of psychedelic medicine.Note: Completing the form does not represent a formal commitment to participate. Additional details about the methodology and next steps will be shared with invited participants in the coming months.If you have any questions about the form or would like to connect further about this work, feel free to reach out to Sara de la Salle at sara.delasalle@mail.mcgill.ca or Dara Menashi at dara@pmhaa.org.

More from June 2025

Advancing Standardized Care Metrics Across the Field

PMHA Alliance Joins Set & Setting Collaborative

New Mexico Psilocybin Pilot Status Report (as of May 2025)

Listening First: How PMHA’s New Mexico Group Psilocybin Study is Being Shaped by Community Design

← All updates See PMHA in the Press & Media →